Skip to main content
. Author manuscript; available in PMC: 2014 Jun 1.
Published in final edited form as: Anticancer Drugs. 2013 Jun;24(5):484–493. doi: 10.1097/CAD.0b013e32835ffdbb

Figure 4. Effect of EHMT2 inhibition on cell invasion and MYCN expression.

Figure 4

(A) Cells were cultured on BD Matrigel invasion chambers for 48 h. Cells were treated with BIX-01294 at a concentration of 1 μg/ml for 48 h in the chambers. Invaded cells were stained and the number of invaded cells in each field was counted under microscopic fields at 200× magnification. Experiments were carried out in triplicate. * p< 0.05 compared with control group. (B) LA1-55n cells were treated with BIX-01294 at a concentration of 5 μg/ml for 24 h. The expression of MYCN was examined by real-time PCR in the vehicle and BIX-01294 treated LA1-55n cells. (C) LA1-55n cells were treated with BIX-01294 at concentration of 5 μg/ml for 48 h. The expression of MYCN was examined by real-time PCR in the vehicle and BIX-01294 treated LA1-55n cells. * represents a statistical significance (p<0.01) between the vehicle- and BIX-01294-treated cells. (D) LA1-55n cells were treated with BIX-01294 at concentration of 1, 2.5, and 5 μg/ml for 24 h. The protein level of MYCN was examined by Western blot analysis in the cell lysis from vehicle and BIX-01294 treated LA1-55n cells. β-actin was used as an endogenous control.